Literature DB >> 27130238

Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.

Kemi M Doll1, Ke Meng2, Paola A Gehrig3, Wendy R Brewster3, Anne-Marie Meyer2.   

Abstract

BACKGROUND: High-volume center surgery and gynecologic oncology care are associated with improved outcomes for women with uterine cancer. Referral patterns, from biopsy through to chemotherapy, may have patients interacting with high-volume centers for all, a portion, or none of their care. The relative frequency, the underlying factors that contribute to referral, and the potential impact of these referral patterns on treatment outcomes are unknown.
OBJECTIVE: We sought to analyze the referral patterns and subsequent impact of care sites on treatment for women with high- and low-risk uterine cancer. STUDY
DESIGN: This is a population-based retrospective cohort study of uterine cancer cases from 2004 through 2009 in North Carolina. Using state cancer registry files linked to Medicare, Medicaid, and private payer insurance claims, we analyzed referral and treatment patterns by annual surgical volume (high ≥12/y). We examined clinical and demographic factors associated with referral and used modified Poisson regression to evaluate risk of referral, lymphadenectomy, and chemotherapy. Stratified Kaplan-Meier plots and Cox proportional hazard models were used to examine survival.
RESULTS: A total of 2053 women were analyzed, including 34% (n = 677) with grade 3 histology. Of 1630 (80%) women with preoperative biopsies, referral patterns (biopsy to surgery) were: low volume to high volume (n = 652, 40%), followed by high volume to high volume (n = 605, 37%), then low volume to low volume (n = 318, 20%), and the rare high volume to low volume (n = 50, 3%). Women retained in low-volume centers after biopsy were older, were less likely to have private insurance, and had more comorbidities. High-risk histology (aRR, 1.14; 95% confidence interval, 1.04-1.25) was positively associated with referral, while Medicaid insurance was negatively associated with referral (aRR, 0.64; 95% confidence interval, 0.42-0.96). Most women (74%, n = 1557) had surgery at high-volume centers. Lymphadenectomy was less likely at low-volume centers (aRR, 0.71; 95% confidence interval, 0.64-0.77). Similarly, for high-risk patients, the relationship between low-volume center surgery and subsequent chemotherapy was aRR, 0.71 (95% confidence interval, 0.48-1.02). Of 290 women who received chemotherapy, the referral patterns (surgery to chemotherapy) were: high volume-all (high volume to high volume), high volume-hybrid (high volume to low volume, or low volume to high volume), and high volume-none (low volume to low volume). In all, 36% (n = 104/290) received chemotherapy at a low-volume center, the majority (68%, n = 71/104) of whom were referred from high-volume centers after surgery. Crude, unadjusted mortality risk of chemotherapy recipients differed by referral pattern (surgery to chemotherapy): high volume-all patients (hazard ratio, 1.0; referent), followed by high volume-hybrid (hazard ratio, 1.33; 95% confidence interval, 0.93-1.91) then high volume-none patients (RR, 1.95; 95% confidence interval, 1.24-3.08).
CONCLUSION: Most women with uterine cancer treated at high-volume centers arrive through referral, which is affected by age and type of insurance, in addition to histology. For high-risk women who require chemotherapy, survival may be related to the extent of treatment received at high-volume centers.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  high volume; outcomes; treatment patterns; uterine cancer

Mesh:

Year:  2016        PMID: 27130238      PMCID: PMC5045768          DOI: 10.1016/j.ajog.2016.04.020

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

1.  Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer.

Authors:  Jason D Wright; Dawn L Hershman; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Sharyn N Lewin; Thomas J Herzog
Journal:  Ann Surg Oncol       Date:  2011-10-12       Impact factor: 5.344

2.  The challenge of churning. Insurers and states seek to ensure coverage continuity between Medicaid and private plans.

Authors:  Virgil Dickson
Journal:  Mod Healthc       Date:  2014-07-28

3.  A combined comorbidity score predicted mortality in elderly patients better than existing scores.

Authors:  Joshua J Gagne; Robert J Glynn; Jerry Avorn; Raisa Levin; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

4.  Endometrial cancer surgery in Arizona: a statewide analysis of access to care.

Authors:  Ivor Benjamin; Heather Dalton; Yue Qiu; Leslie Cayco; William G Johnson; James Balducci
Journal:  Gynecol Oncol       Date:  2011-01-05       Impact factor: 5.482

5.  Big data for population-based cancer research: the integrated cancer information and surveillance system.

Authors:  Anne-Marie Meyer; Andrew F Olshan; Laura Green; Adrian Meyer; Stephanie B Wheeler; Ethan Basch; William R Carpenter
Journal:  N C Med J       Date:  2014 Jul-Aug

6.  Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Authors:  Jennifer L Lund; Til Stürmer; Linda C Harlan; Hanna K Sanoff; Robert S Sandler; Maurice Alan Brookhart; Joan L Warren
Journal:  Med Care       Date:  2013-05       Impact factor: 2.983

7.  Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer.

Authors:  Jason D Wright; Sharyn N Lewin; Israel Deutsch; William M Burke; Xuming Sun; Thomas J Herzog
Journal:  Obstet Gynecol       Date:  2011-05       Impact factor: 7.661

8.  Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

Authors:  Amanda Nickles Fader; Christa Nagel; Allison E Axtell; Kristine M Zanotti; Joseph L Kelley; Kathleen N Moore; Angeles Alvarez Secord; Christine S Walsh; Warner K Huh; Paola A Gehrig; Heidi Gibbons; Peter G Rose; Laura J Havrilesky; Erin Tuller; Richard D Drake; Justin Bottsford-Miller; David M O'Malley
Journal:  Gynecol Oncol       Date:  2009-01-01       Impact factor: 5.482

9.  Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.

Authors:  Amanda Nickles Fader; Richard D Drake; David M O'Malley; Heidi E Gibbons; Warner K Huh; Laura J Havrilesky; Paola A Gehrig; Erin Tuller; Allison E Axtell; Kristine M Zanotti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

10.  Access to cancer services for rural colorectal cancer patients.

Authors:  Laura-Mae Baldwin; Yong Cai; Eric H Larson; Sharon A Dobie; George E Wright; David C Goodman; Barbara Matthews; L Gary Hart
Journal:  J Rural Health       Date:  2008       Impact factor: 4.333

View more
  4 in total

Review 1.  Should Endometrial Cancer Treatment Be Centralized?

Authors:  Vincenzo Dario Mandato; Andrea Palicelli; Federica Torricelli; Valentina Mastrofilippo; Chiara Leone; Vittoria Dicarlo; Alessandro Tafuni; Giacomo Santandrea; Gianluca Annunziata; Matteo Generali; Debora Pirillo; Gino Ciarlini; Lorenzo Aguzzoli
Journal:  Biology (Basel)       Date:  2022-05-18

2.  Association of Delays in Surgery for Melanoma With Insurance Type.

Authors:  Adewole S Adamson; Lei Zhou; Christopher D Baggett; Nancy E Thomas; Anne-Marie Meyer
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

3.  Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer.

Authors:  Chalong Cheewakriangkrai; Chumnan Kietpeerakool; Kittipat Charoenkwan; Porjai Pattanittum; Denny John; Apiwat Aue-Aungkul; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2020-03-13

4.  Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma.

Authors:  N Latchana; L Davis; N G Coburn; A Mahar; Y Liu; A Hammad; D Kagedan; M Elmi; M Siddiqui; C C Earle; J Hallet
Journal:  BJS Open       Date:  2018-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.